ABCG2在卵巢黏液性肿瘤中的表达及意义

Abstract
Figure/Table
References (0)
Related Citation (15)

Download: PDF (1246 KB) HTML (1 KB)
Export: BibTeX | EndNote (RIS) Supporting Info

Abstract Objective: To investigate the expression of cancer stem cell marker ABCG2 in ovarian mucinous tumors and its clinical significance. Mehtods: The expression of ABCG2 was detected by immunohistochemical PV-9000 2-step method in 22 cases of ovarian mucinous cystadenoma, 19 cases of ovarian borderline mucinous tumors and 25 cases of ovarian mucinous adenocarcinoma. The relationship between clinicopathologic characteristics was analyzed. Results: The positive expression rate of ABCG2 in ovarian mucinous cystadenoma, ovarian borderline mucinous tumors and ovarian mucinous adenocarcinoma was 18.2%, 47.4% and 80.0%, respectively. The expression level and positive expression rate of ABCG2 in benign mucinous cystadenoma and borderline mucinous tumor, in benign mucinous cystadenoma and mucinous adenocarcinoma, in mucinous borderline tumor and mucinous adenocarcinoma had statistical difference (P<0.05). The expression of ABCG2 in mucinous adenocarcinoma was significantly higher in stage III-IV than that in stage I-II (P<0.05), and it was significantly higher in moderate and poorly differentiated cancer tissues than in well differentiated cancer tissues (P<0.05), but not correlated with patient age (P>0.05). Conclusion: Expression of ABCG2 may participate in ovarian mucinous tumors during the progression from benign to malignant. And the protein detection may have referential significance in the estimation of tumor malignant degree.

Key words： ovarian mucinous tumors cancer stem cell ABCG2 immunohistochemistry

PACS:

Fund:

	Service
	E-mail this article
	Add to my bookshelf
	Add to citation manager
	E-mail Alert
	RSS
	Articles by authors
	ZHANG Qian
	WANG Haiou
	ZHANG Huxiang
	ZHENG Feiyun

URL:

https://xb.wmu.edu.cn/EN/ OR https://xb.wmu.edu.cn/EN/Y2018/V48/I1/46

[1] SIEGEL R L, MILLER K D, JEMAL A. Cancer statistics[J]. CA Cancer J Clin, 2015, 65(1): 5-29.

[2] LIU S, ZHOU J, WEN J, et al. Expression and significance of CD133 and ABCG2 in endometriosis[J]. Clin Exp Obstet Gynecol, 2015, 42(6): 771-775.

[3] GIL J, STEMBALSKA A, PESZ K A, et al. Cancer stem cells: the theory and perspectives in cancer therapy[J]. J Appl Genet, 2008, 49(2): 193-199.

[4] MIRANDA-LORENZO I, DORADO J, LONARDO E, et al.

Intracellular autofluorescence: a biomarker for epithelial cancer stem cells[J]. Nat Methods, 2014, 11(11): 1161-1169.

[5] PISANO C, GREGGI S, TAMBARO R, et al. Activity of chemotherapy in mucinous epithelial ovarian cancer: a retrospective study[J]. Anticancer Res, 2005, 25(5): 3501-3505.

[6] SHIMADA M, KIGAWA J, OHISHI Y, et al. Clinicopathological characteristics of mucinous adenocarcinoma of the ovary[J]. Gynecol Oncol, 2009, 113(3): 331-334.

[7] AHMED N, A BUBAKER K, FINDLAY J, et al. Cancerous ovarian stem cells: obscure targets for therapy but relevant to chemoresistance[J]. J Cell Biochem, 2013, 114(1): 21-34.

[8] LI C, LIU B, WEN Z, et al. Inhibition of CD44 expression by small interfering RNA to suppress the growth and metastasis of ovarian cancer cells in vitro and in vivo[J]. Folia Biol (Praha), 2008, 54(6): 180-186.

[9] VALEN P, BONNET D, DE MARIA R,et al. Cancer stem cell definitions and terminology: the devil is in the details[J]. Nat Rev Cancer, 2012, 12(11): 767-775.

[10] NATARAJAN K, XIE Y, BAER M R, et al. Role of breast cancer resistance protein (BCRP/ABCG2) in cancer drug resistance[J]. Biochem Pharmacol, 2012, 83(8): 1084-1103.

[11] GUZEL E, KARATAS O F, DUZ M B, et al. Differential expression of stem cell markers and ABCG2 in recurrent prostate cancer[J]. Prostate, 2014, 74(15): 1498-1505.

[12] WANG Y H, LI F, LUO B, et al. A side population of cells from a human pancreatic carcinoma cell line harbors cancer stem cell characteristics[J]. Neoplasma, 2009, 56(5): 371-378.

[13] HANG D, DONG H C, NING T, et al. Prognostic value of the stem cell markers CD133 and ABCG2 expression in esophageal squamous cell carcinoma[J]. Dis Esophagus, 2012, 25

(7): 638-644.

[14] LEE S H, KIM H, HWANG J H, et al. Breast cancer resistance protein expression is associated with early recurrence and decreased survival in resectable pancreatic cancer pa-tients[J]. Pathol Int, 2012, 62(3): 167-175.

[15] SHEN W W, ZENG Z, ZHU W X, et al. MiR-142-3p functions as a tumor suppressor by targeting CD133, ABCG2, and Lgr5 in colon cancer cells[J]. J Mol Med (Berl), 2013, 91(8): 989-1000.